Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US

That is the title of a new paper published in Future Oncology with co-authors Tara Graff,Savreet Bains Chawla,Monika Jun,Nicole Heaps,Abualbishr Alshreef,David Tybor,Donald C. Moore,Nadine Zawadzki, and Kathryn Spurrier. The abstract is below: Aim To quantify the time- and cost-savings to US oncology practices from using a single bispecific antibody (bsAb) for both relapsed/refractory (R/R) diffuse…

Read More

As Lung Disease Threatens Workers, Lawmakers Seek Protections for Countertop Manufacturers

César Manuel González, 37, used to work with stone that was engineered to endure: dense, polished slabs designed to outlast the kitchens in which they were installed. Engineered quartz countertops have surged in popularity in the home renovation market, with industry analysts estimating the global engineered stone market at around $30 billion. It’s continuing to…

Read More

Michael Dalton, Ovatient

Michael Dalton is CEO of Ovatient — it’s a telehealth company built on Epic that comes out of health systems (Medical University of South Carolina and Metro Health, Cleveland, OH). It does the integration and care continuity between its medical group and health systems (a little like KeyCare which also serves health system). I asked…

Read More

Cosmetic Surgery Investigation Prompts Warnings for Patients, and a Push for Tighter Safety Standards

An investigation into cosmetic surgery chains by KFF Health News and NBC News has prompted consumer warnings from industry groups representing plastic surgeons and a call for more transparency around physician disciplinary actions in California. The American Society of Plastic Surgeons, which represents 12,000 doctors, is now warning patients to “do their homework” before getting…

Read More

Payers and targeted therapy in oncology

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…

Read More